Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
- Conditions
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02447887
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2023-01-04
- Target Recruit Count
- 57
- Registration Number
- NCT02440464
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Texas /MD Anderson CRC, Houston, Texas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- John L. Reagan
- Target Recruit Count
- 12
- Registration Number
- NCT02412228
- Locations
- 🇺🇸
Memorial Hospital of Rhode Island, Pawtucket, Rhode Island, United States
🇺🇸The Miriam Hospital, Providence, Rhode Island, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 90
- Registration Number
- NCT02410694
- Locations
- 🇦🇹
UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck, Tirol, Austria
🇨🇿Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic, Brno, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT02400437
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 706
- Registration Number
- NCT02312258
- Locations
- 🇧🇷
Clinica Sao Germano, Sao Paulo, Brazil
🇺🇸North County Oncology Medical Clinic Inc, Oceanside, California, United States
🇦🇷Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina
Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02302846
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 236
- Registration Number
- NCT02253316
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 12
- Registration Number
- NCT02176486
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.